Prostate Cancer

Ravi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.

Men with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy experienced an improved, long-lasting overall survival compared with those who received placebo.

The FDA granted priority review to 177Lu-PSMA-617 in pretreated metastatic castration-resistant prostate cancer based on positive survival data from the phase 3 VISION study.

The addition of docetaxel did not improve overall survival for patients with nonmetastatic unfavorable-risk prostate cancer, although it reduced incidence rates of radiation therapy-induced cancer.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk about key findings observed when utilizing cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer.

Acceptable safety was noted with the addition of darolutamide to androgen deprivation therapy and resulted in infrequent extra adverse effects versus placebo in men with nonmetastatic castration-resistant prostate cancer.

Yoga not only yields improvements in physical, mental, and sexual wellbeing, but it may also result in reduced inflammation and antitumor responses in men with prostate cancer.

Ravi Madan, MD, discusses clinical findings utilizing PET imaging and Tc99 scans in patients with metastatic castration-resistant prostate cancer who are being treated with enzalutamide

Patients with metastatic castration-resistant prostate cancer with or without homologous recombination repair gene mutations may derive benefit from olaparib and abiraterone acetate, according data from the phase 3 PROpel trial.

CancerNetwork® spoke with Michael Schweizer, MD, at the 2021 ESMO Congress about his research into the combination of olaparib plus bipolar androgen therapy for patients with castration-resistant prostate cancer.

Drs Brian Helfand and Steven Finkelstein share key takeaways and clinical pearls from the phase 2/3 EMPIRE-1 trial for prostate cancer.

Overall survival in patients with de novo metastatic castration-sensitive prostate cancer improves with addition of prednisone and abiraterone to androgen-deprivation therapy plus docetaxel.

Certain patients with metastatic castration-resistant prostate cancer may have favorable outcomes after receiving nivolumab plus rucaparib.

Durable objective responses coupled with an acceptable safety profile were reported for sabizabulin in patients with metastatic castration-resistant prostate cancer at 2021 ESMO.

Results of the phase 2 SAKK 08/16 trial indicate a benefit to switching to darolutamide maintenance following prior therapies for metastatic castration-resistant prostate cancer.

The combination of abiraterone acetate and prednisolone plus androgen deprivation therapy showed a statistically significant improvement in survival outcomes for patients with nonmetastatic high-risk prostate cancer.

Atezolizumab plus cabozantinib showed significant activity for patients with high-risk metastatic castration-resistant prostate cancer.

Patients with metastatic castration-resistant prostate cancer experienced an improvement in prostate-specific antigen following treatment with pembrolizumab and olaparib.

Notable declines in prostate-specific antigen levels were seen in patients with castration-resistant prostate cancer who received olaparib coupled with bipolar androgen therapy.

An analysis of patients with prostate cancer treated with immune checkpoint blockade indicated that microsatellite instability and mismatch repair may be indicative of response.

Results from the phase 2 ODEZA trial comparing patient preference of antiandrogen agents indicates benefits of darolutamide over enzalutamide in terms of certain cognitive functions in men with metastatic castration-resistant prostate cancer.

Promising responses seen with the combination of pembrolizumab and olaparib in a cohort of patients with metastatic castration-resistant prostate cancer has led to the initiation of a phase 3 trial.

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, review results from the phase 2/3 EMPIRE-1 trial examining the use of ¹⁸F-fluciclovine-PET/CT imaging to guide postprostatectomy salvage radiotherapy for prostate cancer.

Genomic classifier scores and basal-luminal subtypes may be biomarkers of response for patients with nonmetastatic castration-resistant prostate cancer treated with apalutamide plus androgen deprivation therapy.